B
Bullisch
Bullisch · 25%URGN
$7.21
Szenariopreis
$34.560
-1.935 (-5.60%)Zum Schluss
Loading chart…
- Hoch
- 36.910
- Eröffnung
- 36.350
- Volumengewichteter Durchschnittskurs
- 35.24
- Volumen
- 1.06M
- Marktkap.
- 697.98M
- Tief
- 34.260
- Umsatz
- 37.26M
- EV/EBITDA, TTM
- 554.96
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
KI-Analyse of Urogen Pharma Ltd (URGN)
KaufenUrogen Pharma Ltd (URGN) is a good buy right now due to its significant revenue growth and narrowing losses. The current price is $34.56, while the average analyst target price is $60, suggesting a potential upside of 73.5%. Furthermore, the company reported a gross margin of 90.93% in Q2 2026, indicating strong operational efficiency. However, the main risk is its high forward P/E ratio of 36.50, which suggests that the stock may be overvalued if growth does not meet expectations.
Analystenbewertungen (4)
+16.46% Aufwärtspotenzial
Kaufen
3 Kaufen
1 Halten
0 Verkaufen
Aktuell: 34.56
Tief
31.00
Durchschnitt
40.25
Hoch
55.00
Oppenheimer
Überdurchschnittlich
$60
2026-08-06
Oppenheimer
2026-08-06
Kursziel
$60
Überdurchschnittlich
H.C. Wainwright
Kaufen
$75
2026-08-06
H.C. Wainwright
2026-08-06
Kursziel
$75
Kaufen
Guggenheim
Kaufen
$58
2026-08-06
Guggenheim
2026-08-06
Kursziel
$58
Kaufen
TD Cowen
Kaufen
$60
2026-08-05
TD Cowen
2026-08-05
Kursziel
$60
Kaufen
Guggenheim
Kaufen
$42
2026-07-21
Guggenheim
2026-07-21
Kursziel
$42
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Urogen Pharma Ltd (URGN) beträgt 36.50, verglichen mit dem 5-Jahres-Durchschnitt von -3.18.
Alphio-AI-Kursszenarien für URGN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die URGN halten
Event-Zeitleiste
News
9.010-19NewsfilterUroGen's UGN-103 NDA Accepted by FDA for Bladder Cancer Treatment
- 5.009-04Newsfilter
UroGen Pharma Grants RSUs to 19 New Employees
8.508-20NASDAQ.COMUroGen Pharma Enters Investment and License Agreement with IntraGel
8.508-20PRnewswireIntraGel and UroGen Enter Strategic Investment Agreement
- 8.508-20Newsfilter
IntraGel Secures $7 Million Investment from UroGen for TumoCure Development
URGN FAQ – beantwortet von Alphio AI
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Urogen Pharma Ltd (URGN) is a good buy right now due to its significant revenue growth and narrowing losses. The current price is $34.56, while the average analyst target price is $60, suggesting a potential upside of 73.5%. Furthermore, the company reported a gross margin of 90.93% in Q2 2026, indicating strong operational efficiency. However, the main risk is its high forward P/E ratio of 36.50, which suggests that the stock may be overvalued if growth does not meet expectations.
4 analysts cover URGN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 40.25.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.